Since serum APRIL levels were associated with the histology of nephritis, and high serum levels (> 4 ng/mL) of APRIL may predict treatment failure in patients with class III/IV LN on standard course of therapy. This evidence concerns the gene TNFSF13 and lobular neoplasia.